About Us Shaping access. Driving change.
With a shared passion for problem-solving, we want to push the boundaries of what’s possible in rare diseases and oncology. We are driven by our goal of ensuring innovation reaches patients in ways that are sustainable for industry and help society thrive.
As a global, independent pricing and market access consultancy, we are committed to helping our clients overcome their most complex and strategic challenges.


Why Dolon?
Specialist
Narrow specialism brings deep expertise – with a decade of experience exclusively in rare diseases and oncology, we are masters of our niche.
Strategic
We were founded on the fundamental principle of strategy first – with this as our north star, we cut through complexity to deliver clarity.
Analytical
We recognise that robust data drives informed decision-making - Our insights are underpinned with in-house databases, analytics and tools.
Influential
With years at the forefront of shaping access policy in rare diseases and oncology, we bring thought leadership to help our clients pioneer change.
Collaborative
United by a shared drive for innovation and excellence, we’re proud to forge lasting peer-like partnerships with our clients founded on excellence, fresh perspectives, mutual respect and honesty.
View Our Services
Dolon in numbers
Global
experience
50+
Consultants across
US and Europe
Our
locations
2
Headquarters
in London and NY
Diverse
team
18
Nationalities and fluency
in 10+ languages
Our leadership team
We draw on collective expertise, diverse perspectives, and a universal strategic mindset to develop market access solutions with precision and purpose.

Adam HutchingsManaging Partner

Mansi VithlaniPartner

Richard SearPartner

Richard DuttonExecutive Director

Florence ForwardSenior Director

Pippa MacnairSenior Director

Amanda WhittalDirector

Basmah KhogeerDirector

Elena NicodDirector

Emilie DubernayDirector

Max RexDirector

Rob WoodDirector

Tom KellyDirector
Our careers
Be part of shaping a brighter future for rare disease and oncology innovation.